Back to Clinical Trial Search

Clinical Trial

A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment

Cancer Type

Lung

Protocol Number

202207103

Principal Investigator

Waqar, Saiama

Learn more about this study at clinicaltrials.gov

For more information contact us here:

Phone

800-600-3606

Email

[email protected]

Brief Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Protocol Interventions

Drug: AL8326 60 mg
Learn About Clinical Trials

Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.

Call Us Refer a Patient